Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile May 31, 2021

Fibrogen Investor Alert

Newsfile May 30, 2021

ROSEN, A TOP RANKED LAW FIRM, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN

PR Newswire May 29, 2021

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of FibroGen, Inc. of Deadline in Securities Fraud Class Action Lawsuit

Newsfile May 29, 2021

FibroGen Update

Newsfile May 29, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, PTON INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire May 28, 2021

FIBROGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their Options

GlobeNewswire May 28, 2021

FibroGen, Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit

ACCESSWIRE IA May 28, 2021

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

PR Newswire May 28, 2021

FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Fibrogen, Inc. - FGEN

Newsfile May 28, 2021

FIBROGEN SHAREHOLDERS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

ACCESSWIRE IA May 28, 2021

FibroGen Class Action Reminder

Newsfile May 27, 2021

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN

GlobeNewswire May 27, 2021

Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

GlobeNewswire May 27, 2021

FGEN, CAN & RMO Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm

GlobeNewswire May 27, 2021

FibroGen to Present at Upcoming Investor Conferences

GlobeNewswire May 27, 2021

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire May 26, 2021

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm

GlobeNewswire May 26, 2021

Fibrogen Shareholder Notice

Newsfile May 26, 2021

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

PR Newswire May 26, 2021